Referred to the House Committee on Energy and Commerce.
This bill requires the Secretary of Health and Human Services, working with other federal agencies and stakeholders, to maintain and regularly update an Essential Medicines List that includes active pharmaceutical ingredients and finished drugs of concern for public health and national security. It directs HHS to conduct a comprehensive, recurring risk assessment of supply chains for those medicines, identifying foreign reliance, single-source vulnerabilities, domestic manufacturing capacity, and other risks, and to report findings to congressional committees.
Extent of federal authority and data collection: conservatives worry about overreach and trade-secret exposure, while liberals emphasize the need for government coordination to protect public health.
Relative to its intended legislative type, this bill clearly establishes new, ongoing federal duties and reporting requirements (a substantive policy change with reporting and operational elements).
This bill requires the Secretary of Health and Human Services, working with other federal agencies and stakeholders, to maintain and regularly update an Essential Medicines List that includes active pharmaceutical ingredients and finished drugs of concern for public health and national security.
It directs HHS to conduct a comprehensive, recurring risk assessment of supply chains for those medicines, identifying foreign reliance, single-source vulnerabilities, domestic manufacturing capacity, and other risks, and to report findings to congressional committees.
The bill also directs HHS to map pharmaceutical supply chains (from key starting materials through finished dosage forms), use data analytics to identify vulnerabilities, facilitate interagency information sharing about registered establishments and production amounts, and produce regular reports on mapping efforts.
By content alone, this bill is a targeted, administratively focused effort to improve supply-chain visibility and resilience with limited ideological baggage and no explicit new mandatory spending. Those factors increase its prospects. Key frictions include implementation costs (no appropriation specified), potential industry resistance to data-sharing, and interagency coordination burdens. If Congress prioritizes supply-chain and public-health preparedness measures, the bill's chances improve; otherwise it may be deprioritized amid larger legislative items.
Relative to its intended legislative type, this bill clearly establishes new, ongoing federal duties and reporting requirements (a substantive policy change with reporting and operational elements). It defines the core outputs, responsible entities, timelines, and key data categories while integrating with existing statutory authorities.
Extent of federal authority and data collection: conservatives worry about overreach and trade-secret exposure, while liberals emphasize the need for government coordination to protect public health.
These are examples from the analysis, not a ranked list of the most-affected groups.
Extent of federal authority and data collection: conservatives worry about overreach and trade-secret exposure, while liberals emphasize the need for government coordination to protect public health.
A mainstream liberal would likely view this bill favorably as a proactive, government-led effort to identify and reduce risks to patients and public health from drug shortages and fragile supply chains.
They would emphasize its potential to reduce dependence on foreign suppliers, strengthen domestic manufacturing (including advanced manufacturing), and make prevention of shortages a higher priority for the federal government.
They would also welcome the national security framing and the regular reporting requirements that increase transparency to Congress and the public, while pressing for the reports to include equity implications.
A pragmatic centrist would generally view the bill as a sensible, bipartisan-style measure to improve government information and coordination about drug supply risks, while being cautious about costs, duplication, and effectiveness.
They would appreciate the data-driven approach and the reporting deadlines but would want clarity on how the findings lead to actionable remedies and who pays for implementation.
Centrists would balance support for preparedness and national security benefits against concerns about implementation details, possible bureaucratic overlap, and the burden on industry and agencies.
A mainstream conservative would likely be skeptical of the bill’s expansion of federal data collection and interagency coordination, viewing it as an increase in federal oversight over private pharmaceutical supply chains.
They may acknowledge valid national security and emergency-preparedness reasons for better information on essential medicines, but worry about government intrusion into proprietary business information, the potential for regulatory or procurement favoritism toward domestic manufacturing, and the use of authorities like the Defense Production Act.
The conservative view would stress protecting trade secrets, limiting new bureaucratic mandates, and ensuring costs and impacts on industry and consumers are minimized.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
By content alone, this bill is a targeted, administratively focused effort to improve supply-chain visibility and resilience with limited ideological baggage and no explicit new mandatory spending. Those factors increase its prospects. Key frictions include implementation costs (no appropriation specified), potential industry resistance to data-sharing, and interagency coordination burdens. If Congress prioritizes supply-chain and public-health preparedness measures, the bill's chances improve; otherwise it may be deprioritized amid larger legislative items.
The bill has not accumulated any surfaced votes yet.
Extent of federal authority and data collection: conservatives worry about overreach and trade-secret exposure, while liberals emphasize th…
By content alone, this bill is a targeted, administratively focused effort to improve supply-chain visibility and resilience with limited i…
Relative to its intended legislative type, this bill clearly establishes new, ongoing federal duties and reporting requirements (a substantive policy change with reporting and operational elements). It defines the core…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.